Page last updated: 2024-09-02

fingolimod hydrochloride and Epilepsy, Tonic-Clonic

fingolimod hydrochloride has been researched along with Epilepsy, Tonic-Clonic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chaunu, MP; Daelman, L; Maarouf, A; Maitrot, A; Papeix, C; Tourbah, A	1

Other Studies

1 other study(ies) available for fingolimod hydrochloride and Epilepsy, Tonic-Clonic

Article	Year
Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Multiple sclerosis (Houndmills, Basingstoke, England), 2012, Volume: 18, Issue:11 Topics: Adult; Antibodies, Monoclonal, Humanized; Asthenia; Disease Progression; Drug Administration Schedule; Drug Substitution; Epilepsies, Partial; Epilepsy, Tonic-Clonic; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Severity of Illness Index; Sphingosine; Time Factors; Treatment Outcome	2012

Article

Year

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.

Multiple sclerosis (Houndmills, Basingstoke, England), 2012, Volume: 18, Issue:11

Topics: Adult; Antibodies, Monoclonal, Humanized; Asthenia; Disease Progression; Drug Administration Schedule; Drug Substitution; Epilepsies, Partial; Epilepsy, Tonic-Clonic; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Severity of Illness Index; Sphingosine; Time Factors; Treatment Outcome

2012